Investigating how RNA-binding affects treatment resistance in prostate cancer
RNA-binding as a new paradigm for androgen receptor-mediated prostate cancer therapeutic resistance
This study is looking at how a protein called the androgen receptor helps advanced prostate cancer resist treatments, with the goal of finding new ways to improve therapy and help patients live longer, healthier lives.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tulane University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project ID | NIH-11167304 on NIH RePORTER |
What this research studies
This research focuses on understanding how the androgen receptor (AR) contributes to resistance against therapies for advanced prostate cancer. It explores the mechanisms by which AR can reactivate cancer growth despite treatment with drugs like enzalutamide and abiraterone. By examining the RNA-binding capabilities of AR and its role in regulating splicing factors, the study aims to uncover new strategies to delay or prevent disease progression. Patients may benefit from insights that could lead to more effective treatments tailored to combat resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with advanced prostate cancer who have experienced disease progression despite current AR-targeting therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not undergone AR-targeting therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that improve treatment outcomes for patients with advanced prostate cancer.
How similar studies have performed: Previous research has shown promising results in understanding AR's role in cancer progression, suggesting that this approach could yield significant insights.
Where this research is happening
New Orleans, United States
- Tulane University of Louisiana — New Orleans, United States (Active)
Researchers
- Principal investigator: Dong, Yan — Tulane University of Louisiana
- Study coordinator: Dong, Yan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.